In vitro Anticancer Activities of Compounds Containing a Benzimidazole Core and In Silico Pharmacokinetic–Toxicity Analyses

Yıl 2026, Cilt: 9 Sayı: 2, 573 - 584, 15.03.2026

Gülay Dilek

https://doi.org/10.34248/bsengineering.1850439

https://izlik.org/JA53GD48ZP

Öz

Benzimidazole-based compounds are widely recognized as versatile scaffolds in drug discovery due to their structural diversity and broad spectrum of biological activities, including anticancer effects. Breast cancer remains one of the most prevalent malignancies among women worldwide, and the high incidence, mortality rates, and emergence of resistance to current therapies highlight the need for safer and more effective treatment strategies. In this study, two different compounds containing a benzimidazole core (3a and 3b) were prepared, and the structure of the new compound (3b) was characterized using spectroscopic methods. The cytotoxic activities of 3a and 3b were comprehensively evaluated in vitro using two breast cancer cell lines (MCF-7 and MDA-MB-231). The results revealed concentration-dependent cytotoxic effects, with compound 3a showing higher activity against the MCF-7 cell line (IC₅₀ = 88.15 µM) compared to MDA-MB-231 cells (IC₅₀ = 145.80 µM). The pharmacokinetic and toxicological properties of 3a and 3b were predicted using in silico approaches. ADMET analyses and BOILED-Egg model results indicated that compounds 3a and 3b have good oral absorption potential and the possibility of crossing the blood-brain barrier. In silico toxicity assessments revealed that both compounds have an inactive profile in terms of hepatotoxicity, nephrotoxicity, and cardiotoxicity; however, they should be carefully evaluated for neurotoxicity and mutagenicity. Furthermore, based on acute oral toxicity estimates, the LD₅₀ values of the compounds were calculated to be approximately 400 mg/kg, and the toxicity class was determined to be 4.

Anahtar Kelimeler

Cytotoxic activity , Breast cancer , Benzimidazole derivatives , ProTox-II , SwissADME

Etik Beyan

Ethics committee approval was not required for this study because of there was no study on animals or humans.

Teşekkür

The author gratefully acknowledges the technical support provided by Aksen Research Laboratory for the in vitro cytotoxicity assays.

Kaynakça

• Abdullah, M. N., Hamid, S. A., Salhimi, S. M., Jalil, N. A. S., Al-Amin, M., & Jumali, N. S. (2023). Design and synthesis of 1-sec/tert-butyl-2-chloro/nitrophenylbenzimidazole derivatives: Molecular docking and in vitro evaluation against MDA-MB-231 and MCF-7 cell lines. Journal of Molecular Structure, 1277, 134828.
• Akkoç S. 2019. Derivatives of 1-(2-(piperidin-1-yl)ethyl)-1H-benzo[d]imidazole: synthesis, characterization, determining of electronic properties and cytotoxicity studies. ChemistrySelect, 4(17): 4938–4943.
• Akkoç, S. (2021). Design, synthesis, characterization, and in vitro cytotoxic activity evaluation of 1,2-disubstituted benzimidazole compounds. Journal of Physical Organic Chemistry, 34(4), e4125.
• Akkoç, S. (2025). Antiproliferative activity, wound healing, and theoretical computational studies of compounds including the benzimidazole moiety. Biochemical and Biophysical Research Communications, 793, 153006.
• Aktaş, A., Özden, E. M., Celepci, D. B., Taskin-Tok, T., Ekti, F. S., Gülçin, İ., Aygün, M., Gök, Y., & Çelik, İ. (2025). 5(6)-Benzoyl-substituted benzimidazoles and their benzimidazolium salts: Design, synthesis, characterization, crystal structure, and some metabolic enzymes inhibition properties. Archiv der Pharmazie, 358(7), e70063.
• Al-blewi, F. F., Almehmadi, M. A., Aouad, M. R., Bardaweel, S. K., Sahu, P. K., Messali, M., Rezki, N., & El Ashry, E. S. (2018). Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents. Chemistry Central Journal, 12, 110.
• Alheety, N. F., Mohammed, L. A., Majeed, A. H., Aydin, A., Ahmed, K. D., Alheety, M. A., Guma, M. A., & Dohare, S. (2023). Antiproliferative and antimicrobial studies of novel organic-inorganic nanohybrids of ethyl 2-((5-methoxy-1H-benzo[d]imidazol-2-yl)thio)acetate (EMBIA) with TiO2 and ZnO. Journal of Molecular Structure, 1274, 134489.
• Banerjee, P., Eckert, A. O., Schrey, A. K., & Preissner, R. (2018). ProTox-II: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Research, 46(W1), W257–W263.
• Bautista-Aguilera, Ó. M., Manik, A., Diez-Iriepa, D., Szałaj, N., Zaręba, P., Więckowska, A., Żmudzki, P., Honkisz-Orzechowska, E., Knez, D., Gobec, S., Sałat, K., Martínez-Alonso, B., Guarnizo-Herrero, V., Durán, G. T., Torrado-Salmerón, C., Bellver-Sanchis, A., Nsiona-Defise, I., Ribalta-Vilella, M., Pallàs, M., López-Muñoz, F., & Iriepa, I. (2025). N-Methyl-N-((1-methyl-5-(3-(piperidin-1-yl)propoxy)-1H-benzo[d]imidazol-2-yl)methyl)prop-2-yn-1-amine (MBA-159), a new multitarget small molecule for the therapy of Alzheimer’s disease. Biomedicine & Pharmacotherapy, 192, 118603.
• Bilici, E., & Akkoç, S. (2025). In vitro cytotoxicity in A549, Hepg2, MCF-7, and DLD-1 cancer cell lines and ADME/toxin analysis of a benzimidazole derivative. Journal of King Saud University - Science, 37(2), 4242024.
• Cereda, E., Turconi, M., Ezhaya, A., Bellora, E., Brambilla, A., Pagani, F., & Donetti, A. (1987). Anti-secretory and anti-ulcer activities of some new 2-(2-pyridylmethyl-sulfinyl)-benzimidazoles. European Journal of Medicinal Chemistry, 22(6), 527–537.
• Çevik, U. A., Celik, I., Işık, A., Pillai, R. R., Tallei, T. E., Yadav, R., Özkay, Y., & Kaplancıklı, Z. A. (2022). Synthesis, molecular modeling, quantum mechanical calculations and ADME estimation studies of benzimidazole-oxadiazole derivatives as potent antifungal agents. Journal of Molecular Structure, 1252, 132095.
• Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717.
• Dilek, G., Muhammed, M. T., & Akkoç, S. (2025). Synthesis, antiproliferative activity evaluation, and computational insights of benzo[d]imidazol-2(3H)-one derivatives. ChemistrySelect, 10(33), e03640.
• Donthiboina, K., Anchi, P., Gurram, S., Sai Mani, G., Lakshmi Uppu, J., Godugu, C., Shankaraiah, N., & Kamal, A. (2020). Synthesis and biological evaluation of substituted N-(2-(1H-benzo[d]imidazol-2-yl)phenyl)cinnamides as tubulin polymerization inhibitors. Bioorganic Chemistry, 103, 104191.
• Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021). Cancer statistics for the year 2020: An overview. International Journal of Cancer, 149(4), 778–789.
• Gutiérrez-Hernández, A., Estrada-Soto, S., Martínez-Conde, C., Gaona-Tovar, E., Medina-Franco, J. L., Hernández-Núñez, E., Hidalgo-Figueroa, S., Castro-Moreno, P., Ibarra-Barajas, M., & Navarrete-Vazquez, G. (2024). Synthesis, biosimulation and pharmacological evaluation of benzimidazole derivatives with antihypertensive multitarget effect. Bioorganic & Medicinal Chemistry Letters, 110, 129879.
• Husain, A., Bhutani, M., Parveen, S., Khan, S. A., Ahmad, A., & Iqbal, M. A. (2021). Synthesis, in vitro cytotoxicity, ADME, and molecular docking studies of benzimidazole-bearing furanone derivatives. Journal of the Chinese Chemical Society, 68(2), 362–373.
• Imran, M., Shah, F. A., Nadeem, H., Zeb, A., Faheem, M., Naz, S., Bukhari, A., Ali, T., & Li, S. (2021). Synthesis and biological evaluation of benzimidazole derivatives as potential neuroprotective agents in an ethanol-induced rodent model. ACS Chemical Neuroscience, 12(3), 489–505.
• Kızılyıldırım, S., Sucu, B., Muhammed, M. T., Akkoç, S., Esatbeyoglu, T., & Ozogul, F. (2025). Experimental and theoretical studies on antituberculosis activity of different benzimidazole derivatives. Heliyon, 11(4), e42674.
• Kundu, S., Feizi-Dehnayebi, M., & Akkoç, S. (2025). Exploring the anticancer potential of novel benzimidazolium salts: Synthesis, biological evaluation, DFT perspective, and docking simulation for inhibition of VEGFR2. Biochemical and Biophysical Research Communications, 780, 152472.
• Naz, H., Othman, M. S., Rahim, F., Hussain, R., Khan, S., Taha, M., Hafez, M. M., Abdel-Hafez, L. J. M., Ullah, H., Khan, I. U., Khan, Y., & Shah, S. A. A. (2024). Investigation of novel benzimidazole-based indole/thiazole hybrids derivatives as effective anti-diabetics and anti-Alzheimer's agents: Structure–activity relationship insight, in vitro and in silico approaches. Journal of Molecular Structure, 1312, 138592.
• Patel, V. M., Patel, N. B., Chan-Bacab, M. J., Rivera, G., Humal, T. R., & Gamit, A. S. (2025). Synthesis and computational studies of 1,3,4-thiadiazole and benzothiazole clubbed benzimidazole analogous as anti-tubercular and anti-protozoal agent. Journal of Molecular Structure, 1319, 139326.
• Raducka, A., Świątkowski, M., Gobis, K., Szymański, P., & Czylkowska, A. (2022). In silico ADME and toxicity prediction of benzimidazole derivatives and its cobalt coordination compounds. Synthesis, characterization and crystal structure. Molecules, 27(22), 8011.
• Rodríguez-Mora, M. I., Colorado-Peralta, R., Reyes-Márquez, V., García-Eleno, M. A., Cuevas-Yáñez, E., Parra-Unda, J. R., Landa, A., & Morales-Morales, D. (2024). Effect of fluorine substituents in 4-(1-benzyl-1H-benzo[d]imidazol-2-yl)thiazole for the study of antiparasitic treatment of cysticercosis on a Taenia crassiceps model. RSC Pharmaceutics, 1(5), 1055–1065.
• Taha, M., Rahim, F., Adalath, B., Imran, S., Mohammed Khan, K., Adnan Ali Shah, S., Uddin, N., Nawaz, M., Bin Break, M. K., Magam, S. M., & Alqarni, S. (2024). Synthesis of benzimidazole derivatives and their antiglycation, antioxidant, antiurease and molecular docking study. Arabian Journal of Chemistry, 17(4), 105700.